HAVCR2 and diffuse large B-cell lymphoma: (125) suggested that TIM-3+ Foxp3+ Treg (TFT) cells are highly enriched in the TME of diffuse large B-cell lymphoma (DLBCL) and the abundance of TFT cells is correlated with a poor prognosis in patients with DLBCL, while the TIM-3 antibody is capable of inhibiting IL-10 secretion.